committed to innovation and growth - roche.com230fd9bd-942e-4f39-bde4-0a2e005b… · 1europe,...
TRANSCRIPT
2014 Group results
Diagnostics
Business model & strategy
2014 overview
Building a leading sequencing solution
Outlook
2
2014: Targets achieved
3
Targets for 2014 FY 2014
Group sales Low to mid-single digit growth1 +5%
Core EPS Ahead of sales growth1
+5%
+7% excl. one-time
US Pharma fee2
Dividend Further increase dividend3 CHF 8.00
+3%
1 At constant exchange rates 2 One-time double charge of CHF 202m for the US Branded Prescription Drug fee in 2014, following final regulations issued by the US
Internal Revenue Service which advanced the timing of recording the liability 3 2014 dividend as proposed by the Board of Directors
First take on Swiss National Bank`s decision
4
On January 15, the Swiss National Bank (SNB) announced its decision to unpeg
the Swiss franc from the Euro
Natural hedge of the underlying business:
• 18% of operating costs in Switzerland
• US, Europe, Japan and China with complete value chain
• Interest expenses predominantly paid in USD
• 2015 dividend payout for March converted prior to SNB decision
2014: Solid sales growth
5
2014 2013
CHFbn CHFbn CHF CER
Pharmaceuticals Division 36.7 36.3 1 4
Diagnostics Division 10.8 10.5 3 6
Roche Group 47.5 46.8 1 5
Change in %
CER=Constant Exchange Rates
2014: Continued sales growth for 4 years
6
0% 0% 1%
4%
2%
6%
4%
6% 6%
4%
8%
7%
5%
4%
5%
6%
0%
2%
4%
6%
8%
10%
Q1
11
Q2
11
Q3
11
Q4
11
Q1
12
Q2
12
Q3
12
Q4
12
Q1
13
Q2
13
Q3
13
Q4
13
Q1
14
Q2
14
Q3
14
Q4
14
All growth rates at Constant Exchange Rates (CER)
2014: Group core operating profit & margin
remains at high levels
7
16.6
15.1
17.2 17.9 17.6
34.9% 35.6% 37.7% 38.3%
37.2%
2010 2011 2012 2013 2014
+3% at CER (+5%*) % of sales
CHFbn
(37.6%*)
CER=Constant Exchange Rates
* Excluding one-time double charge for the US Branded Prescription Drug fee in 2014
2014: Dividend and payout ratio further increased
8 1 compound annual growth rate
8.00
31.9 34.5
38.8
44.8
48.6
51.6
55.3
54.5
54.7 56.0
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014
Dividend payout ratio (%) CHF
2014 payout ratio: 56.0%
Payout ratio calculated as dividend per share divided by core earnings per share (diluted); 2014 dividend as proposed by the Board of
Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996
2014 Group results
Diagnostics
Business model & strategy
2014 overview
Building a leading sequencing solution
Outlook
9
In-Vitro Diagnostics market overview
Large and growing market; Roche is market leader
10
Source: Roche Analysis, Company reports for 2013 validated by an independent IVD consultancy
Market share
20%
11%
10%
8% 7% 3%
40%
Roche
Abbott
Siemens
J&J Danaher
Biomerieux
Others
Market size
USD 52 bn
Molecular Diagnostics
Professional Diagnostics
Tissue Diagnostics
Diabetes Monitoring
Our business model
Place instruments to generate recurring revenues through reagent usage
11
Closed
Systems
best instrument technology broadest menu
Our strategy
Differentiation through innovation in testing efficiency and medical value
12
2012 2020
Medical
Value
Drivers of
competitive differentiation
Testing
Efficiency
2014 Group results
Diagnostics
Business model & strategy
2014 overview
Building a leading sequencing solution
Outlook
13
2014: Diagnostics Division sales
Growth driven by Professional Diagnostics
14
2014 2013
CHFm CHFm CHF CER
Diagnostics Division 10,766 10,476 3 6
Professional Diagnostics 6,045 5,772 5 8
Diabetes Care 2,392 2,459 -3 1
Molecular Diagnostics 1,613 1,580 2 6
Tissue Diagnostics 716 665 8 10
Change in %
Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8%
CER=Constant Exchange Rates
North America
+4%
25% of divisional sales
Latin America
+13%
7% of divisional sales
Japan
0%
4% of divisional sales EMEA1
+4%
45% of divisional sales
2014: Diagnostics regional sales
Growth driven by APAC and EMEA
Asia Pacific
+15%
19% of divisional sales
15
16% growth in E7 countries2
1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates
2014: Diagnostics Division
Profit growth in line with sales excl. PSI*
16 CER=Constant Exchange Rates
* PSI: 2013 past service income of CHF 67m; VAT: 2013 one-time VAT refund of CHF 45m
CHFm % sales
Sales 10,766 100.0
Royalties & other op. inc. 131 1.2
Cost of sales -4,790 -44.4
M & D -2,462 -22.9
R & D -1,037 -9.6
G & A -512 -4.8
Core operating profit 2,096 19.5
2014 2014 vs. 2013
CER growth
-4% in CHF
6%
2%
9%
4%
3%
21%
2%
Admin: +6%
Excl. PSI*: +5%
Excl. PSI*: +5%
and VAT*: +8%
Excl. VAT*: +8%Excl. VAT*: +8%
2014: Diagnostics
Growth driven by Professional Diagnostics
+1%
• Virology (+7%) incl. HPV (+48%) • Launch of cobas 6800/8800 systems with assays for blood
screening and virology
• Accu-Chek Aviva/Performa (+7%) and Mobile (+19%)
• Advanced staining portfolio (+9%) and companion
diagnostics (+27%)
1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa
CER growth
1
+8%
+6%
+10%
• Continued double digit growth in immunodiagnostics (+13%)
• Further expansion of leading menu
0 1 2 3 4 5 6
Tissue Dia
Molecular
Dia
Diabetes
Care
Professional
Dia
EMEA
North America
RoW
Sales
CHFbn
17
Serum work area (42% of sales)*
Growing strongly in all regions
18
+5%
+8%
+15%
+19%
+8%
+10%
EMEA
Asia-Pacific
North America
Japan
Latin America
*SWA: serum work area: clinical chemistry and immunodiagnostics
2013 2014
Integrated SWA* solution
– Immunodiagnostics (+13%)
– Clinical chemistry (+7%)
Invest for growth
New reagent manufacturing in China
• Reliable local supply and right
sizing of cost base
• Reagent formulation, filling and
packaging
– Packaging to begin in 2016
– Fully operational in 2018
2012 2022E 2017E
Other
Asia
RPD reagent volume
x2
19 RPD = Roche Professional Diagnostics
Extend leading menu in women’s health
High prognostic value of preeclampsia blood test
21
Assay and claim extension
• Extends the applicability of the assay
from 3-5% of pregnancies to 20%
• Fully automated
• Test performed across entire cobas
analyzer platform series
* Hund, M., et al. (2014) BMC Pregnancy and Childbirth 14, 324;
Zeisler, H.,. et al. (2014) XX COGI World Congress 2014
*Preeclampsia can be ruled-out for 1 week after testing
Medium Hospitals
Large Hospitals
Reference Labs
High Throughput
Low Throughput
cobas® 6800
cobas® 4800
cobas® 8800
Molecular Diagnostics
Launch and implementation of cobas 6800/8800
• Advanced PCR automation
• Highest throughput (3x above closest
competitor)
• CE launch of blood screening and
virology assays
• Low to middle volume throughput
• Broadest menu incl HPV testing
22
Entering Molecular Point of Care Diagnostics
Acquisition of IQuum, launch of cobas Liat™ analyzer
23
Target market:
• ~CHF 350m, growing ~20% p.a.
Laboratory in a tube technology:
• Fast and easy to use
• CLIA waiver expected in 2015
Portfolio:
• Influenza A/B and Strep A test, CE marked and FDA cleared
• Plans to extend menu in:
– Respiratory Syncytial Virus tests
– MRSA and C-difficile
Liat™ Analyzer Liat™ tube
Point of Care: e.g. physician’s office, emergency rooms, ambulance, pharmacies; MRSA: methicillin resistant Staphilococcus aureus
2014 Group results
Diagnostics
Business model & strategy
2014 overview
Building a leading sequencing solution
Outlook
24
DNA testing market*: 10-year estimates
Next-generation sequencing (NGS) will be the
fastest-growing segment
DNA testing uses different
technologies which are complementary
in applications:
• Molecular (PCR):
– virology
– blood screening
– Oncology
– Infectious disease
• In situ hybridization (ISH)
– oncology
• Sequencing:
– Whole genome sequencing and
targeted sequencing
– Mutation detection
– Oncology
– Pre-natal, newborn
– Infectious disease
Roche is market leader in DNA testing Complement offering with leading sequencing solution
* Includes Lab developed tests; PCR: polymerase chain reaction; Sanger: oldest sequencing technology; ISH: in situ hybridization
Sequencing strategy
Building a leading sequencing solution
26
Grow through
disruptive
innovation
Sample
preparation
Testing
platform
Menu of
assays
Data
analysis Reporting
Developing complete sequencing solutions
Abvitro: Technology acquisition; Ariosa: Acquisition; Genia: Acquisition; Pacific Biosciences: Partnership; Bina: Acquisition; Foundation Medicine: Partnership
Sequencing menu: Non-invasive prenatal testing
Acquisition of Ariosa
27
Target market
• USD 400m sales worldwide in 2013, +30% pa
Technology
• Analyses fetal DNA with microarray technology
• Highly cost effective and accurate
• Screens for the risk of Down, Edwards and Patau
syndrome
Strategy
• Expand market access through kit distribution model
• Add test to Roche sequencing platform when available
HarmonyTM Prenatal Test
Digital analysis of selected
regions (DANSRTM) technology
2014 Group results
Diagnostics
Business model & strategy
2014 overview
Building a leading sequencing solution
Outlook
28
1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics;
RTD: Roche Tissue Diagnostics;
Key launches 2015
29
Area Product Market BA1
Instruments
/
Devices
Laboratory
cobas c 513 – dedicated HbA1C analyzer
cobas t 411– core lab coagulation analyzer
cobas 8100 V2 – Integrated pre- and post-analytical solution
cobas® 6800/8800 – Medium to High volume automated real-time PCR
VENTANA HE 600 – automated H&E staining platform
EU
EU
WW
US
WW
RPD
RPD
RPD
RMD
RTD
Diabetes
Care
Accu-Chek Active no-code– next-gen. bG meter, no coding of test strips
Accu-Chek Connect – bG meter with connectivity to smartphones, mobile
applications and cloud
WW
US
RDC
RDC
Point of Care CoaguChek® Pro II - professional system for PT and aPTT testing EU RPD
Tests
/
Assays
Blood
Screening cobas® 6800/8800 MPX – Multiplex Bloodscreening test US RMD
Infectious
Diseases
cobas® Liat Influenza A/B + RSV – POC detection
HTLV– human T-lymphotropic virus diagnostics test
US
EU
RMD
RPD
Virology
cobas® 6800/8800 HBV – Quantitative HBV viral load test
cobas® 4800 HIV-1 - Quantitative HIV viral load test
cobas® 4800 HCV – Quantitative HCV viral load test
cobas® 4800 HBV – Quantitative HBV viral load test
EU
EU
EU
EU
RMD
RMD
RMD
RMD
Genomics &
Oncology cobas® EGFR Test v2 - detection of EGFR in plasma EU RMD
Cardiac Cobas h 232 Troponin T – Point of Care test version of Elecsys cTNT-hs EU RPD
Outlook
Investing into future growth
• Continued strong growth in serum work area
• Focus on implementation of next generation platforms, e.g. cobas 6800/8800
• Continued investment into development of future sequencing solution
• Ongoing structural adjustments in Diabetes Care to adapt to continuing
challenging market environment
• Strengthen leading presence in emerging markets
30
Rituxan/MabThera RA
Neuroscience
6 NMEs
ocrelizumab
gantenerumab
Roche: A pipeline of differentiated products
Launched
Phase III
Phase II 10 NMEs + 9 AIs
Rituxan/MabThera
Xeloda
Herceptin
Perjeta
Kadcyla
Avastin
Gazyva/Gazyvaro
Tarceva
Zelboraf
Erivedge
Immunology/
Ophthalmology
Actemra/RoActemra
Lucentis
Xolair
Esbriet
Pulmozyme
lebrikizumab
lampalizumab3
etrolizumab2
anti-PDL1
taselisib1
venetoclax (Bcl2i)
cobimetinib4
pictilisib1
alectinib
31
Oncology
Neuroscience
Ophthalmology
Immunology
Oncology
3 AIs
1 Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma
AI = Additional Indication; NME = New Molecular Entity
2015: Key late-stage news flow
32
Compound Indication Milestone
Regulatory
Avastin Cervical cancer EU approval
Lucentis Diabetic retinopathy US approval
alectinib ALK+ NSCLC US filing
Cobimetinib + Zelboraf 1L Melanoma US, EU approval
Phase III readouts*
Gazyva Front line aNHL Ph III GOYA (interim)
ocrelizumab Relapsing MS (RMS) Ph III OPERA I/II
ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO
Perjeta 2L HER2+ mBC Ph III PHEREXA
Kadcyla HER2+ gastric cancer Ph II/III GATSBY
Phase III starts
Anti-PDL1 Bladder Ph III
Anti-PDL1 Tumor type 1 Ph III
Anti-PDL1 Tumor type 2 Ph III
Anti-PDL1 Tumor type 3 Ph III
Etrolizumab Crohn`s disease Ph III
ACE910 Hemophilia A Ph III
taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER
Phase II readouts*
Anti-PDL1 2/3L NSCLC Ph II FIR, POPLAR, BIRCH
Anti-PDL1 Bladder Ph II
ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR
* Outcome studies are event driven, timelines may change
Roche Group development pipeline
33
Phase I
(33 NMEs + 11 AIs)
Raf & MEK dual inh solid tumors
venetoclax (Bcl-2) heme indications
ChK1 inh solid tum & lymphoma
Oncology Other disease areas
Status as of January 28, 2015
HER3 MAb solid tumors
MDM2 ant solid & hem tumors
New Molecular Entity (NME) Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other
RG-No Roche Genentech managed
CHU Chugai managed
PD-L1 MAb+Zelboraf+/-cobimetinib m. melanoma
Steap 1 ADC prostate ca.
PD-L1 MAb+Avastin+chemo solid tumors
PD-L1 MAb solid tumors
PD-L1 MAb+cobimetinib solid tumors
venetoclax (Bcl-2)+ Gazyva CLL CLL
PD-L1 MAb+Tarceva NSCLC EGFR+
ERK inh solid tumors
CEA IL2v solid tumors
LSD1 inh AML
ADC solid tumors
MDM2 (4) IV prodrug AML
ADC ovarian ca
PD-L1 MAb+ipi/IFN solid tumors
OX40 MAb solid tumors
Lucentis sust. deliv. AMD/RVO/DME
PDE10A inh schizophrenia
Nav1.7 inh pain
VEGF-ANG2 MAb wAMD
TAAR1 ago schizophrenia
a-synuclein MAb Parkinson's Disease
mGlu5 PAM schizophrenia
SMN2 splicer spinal muscular atrophy
TLR7 agonist HBV RG7795
RG3645
RG7203
RG7893
aldosterone synth inh met. diseases RG7641
RG7716
RG7410
RG7935
RG7342
RG7800
HIF1 alpha LNA solid tumors
RG7304
RG7601
RG7741
RG7116
RG7388
RG7446
RG7450
RG7446
RG7446
RG7446
RG7601
RG7446
RG7842
RG7813
RG6016
RG7841
RG7775
RG7882
RG7446
RG7888
RG6061
CEA CD3 TCB solid tumors RG7802
CD40 iMAb+PD-L1 MAb solid tumors RG7876
MSLN PE cFP solid tumors RG7787
PD-L1 MAb+Gazyva lymphoma RG7446
- autoimmune diseases RG7880
autoimmune diseases RG7625
- infectious diseases RG7689
DBO β-lactamase inh bact. infections RG6080
TAUpS422 MAb Alzheimer’s RG7345
CSF-1R + PDL-1 MAb solid tumors RG7155
SERD (2) ER+(HER2-neg) mBC RG6047
IDO inh solid tumors RG6078
HER3/EGFR DAF+ cobi KRAS+ s. tumors RG7597
New Molecular Entity (NME)
Additional Indication (AI)
RG-No Roche Genentech managed
CHU Chugai managed
RG105 MabThera is branded as Rituxan in US and Japan
RG1569 Actemra is branded as RoActemra in EU
RG7159 Gazyva is branded as Gazyvaro in EU
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other
Roche Group development pipeline
34
Phase II
(23 NMEs + 12 Als)
Phase III
(9 NMEs + 21 Als)
Registration
(1 NME + 4 Als)
1 US only : FDA submission decision pending
2 Approved in US, submitted in EU
3 Submitted in US
crenezumab Alzheimer’s RG7412
lampalizumab (factor D) geo. atrophy RG7417
Lucentis diabetic retinopathy RG36453
Avastin recurrent cervical cancer RG4352
Perjeta HER2+ BC neoadj RG12732
cobimetinib + Zelboraf m. melanoma RG7421
MabThera SC CLL RG105
Status as of January 28, 2015
Avastin glioblastoma 1st line RG4351
Avastin NSCLC adj RG435
Kadcyla +/- Perjeta HER2+ mBC 1st l RG3502
ocrelizumab RMS RG1594
Gazyva DLBCL 1st line RG7159
ocrelizumab PPMS RG1594
Actemra large-vessel vasculitis CHU
lebrikizumab severe asthma RG3637
Zelboraf melanoma adj RG7204
Perjeta HER2+ gastric cancer 1st line RG1273
Actemra giant cell arteritis RG1569
etrolizumab ulcerative colitis RG7413
Perjeta HER2+ mBC 2nd line RG1273
alectinib (ALK inhibitor) NSCLC RG7853
Gazyva iNHL rituximab refractory RG7159
Gazyva follicular lymphoma 1st line RG7159
venetoclax (Bcl-2) + Rit. CLL rel/ref RG7601
Kadcyla HER2+ gastric cancer 2nd line RG3502
gantenerumab Alzheimer’s RG1450
PD-L1 MAb NSCLC 2nd line RG7446
Kadcyla + Perjeta HER2+ BC adj RG3502
Kadcyla + Perjeta HER2+ BC neoadj RG3502
IL-6R MAb neuromyelitis optica CHU
Perjeta HER2+ BC adj RG1273
Kadcyla HER2+ BC adj RG3502
venetoclax+Gazyva (Bcl-2) CLL 1st line RG7601
Avastin ovarian cancer 1st line RG4351
Avastin rel. ovarian ca. Pt-sensitive RG4351
PD-L1 MAb bladder cancer 2nd line RG7446
bitopertin obsessive compulsive dis. RG1678
danoprevir HCV RG7227
basimglurant (mGlu5 NAM) TRD RG7090
MAO-B inh Alzheimer’s RG1577
Actemra systemic sclerosis RG1569
polatuzumab vedotin (CD79bADC) hem tumors RG7596
V1 receptor antag autism RG7314
ipatasertib (AKT inh) solid tumors RG7440
lebrikizumab idiopathic pulmonary fibrosis RG3637
LptD antibiotic antibacterial
RG7929
venetoclax (Bcl-2) C LL rel/refract 17pdel RG7601
PD-L1 MAb bladder cancer 1/2l RG7446
Flu A MAb influenza RG7745
IL-31R MAb atopic dermatitis CHU
FIXa /FX bispecific MAb hemophilia A RG6013
PD-L1 MAb NSCLC 2nd/3rd line RG7446
GABRA5 NAM Down Syndrome RG1662
ADC lifastuzumab vedotin (NaPi2bADC)Pt-resist. OC RG7599
PD-L1 MAb + Avastin RCC RG7446
CSF-1R MAb PVNS/solid tumors RG7155
taselisib (mutant-selective) solid tumors RG7604
venetoclax (Bcl-2) DLBCL RG7601
Ang2-VEGF MAb colorectal cancer RG7221
setrobuvir HCV RG7790
glypican-3 MAb liver cancer RG7686
GIP/GLP-1 dual ago type 2 diabetes RG7697
Esbriet SSc – interstitial lung disease RG6062
cobimetinib TNBC RG7421
Avastin+Tarceva EGFR mut+ NSCLC RG435
venetoclax (Bcl-2)+ Rituxan rel/ref FL RG7601
pictilisib pictilisib solid tumors RG7321
SERD ER+(HER2-neg) mBC RG6046
URAT 1 inh gout CHU
RG7929
Kadcyla HER2+ NSCLC RG3502
lebrikizumab IPF RG3637
NME submissions and their additional indications
Projects currently in phase 2 and 3
35
Unless stated otherwise, submissions are planned to occur in US and EU
* lead market China
Neuroscience
Ophthalmology
Other
NME
Oncology
Immunology
Infectious Diseases
CardioMetabolism
bitopertin (RG1678)
obsessive compulsive dis.
ocrelizumab (RG1594) RMS
cobimetinib (MEK inh) combo Zelboraf
met melanoma
danoprevir* (RG7227) HCV
basimglurant (RG7090) depression
crenezumab (RG7412) Alzheimer‘s
gantenerumab (RG1450) Alzheimer‘s
V1 receptor antag (RG7314) autism
glypican-3 Mab (RG7686) liver cancer
lampalizumab anti-factor D (RG7417) geo atrophy
lebrikizumab (RG3637) severe asthma
etrolizumab (RG7413) ulcerative colitis
2014 2015 2017 and beyond
alectinib (RG7853) ALK-pos. NSCLC
PD-L1 MAb (RG7446) NSCLC 2nd/3rd line
ipatasertib AKT inh (RG7440) solid tumors
MAO-B inh (RG1577) Alzheimer‘s
polatuzumab vedotin (RG7596)
CD79b ADC heme tumors
LptD antibiotic (RG7929) antibacterial
lebrikizumab (RG3637) idiopathic pulmonary fibrosis
2016
PDL-1 MAb (RG7446) combo Avastin RCC
Flu A MAb (RG7745) influenza
taselisib (PI3Ki, RG7604) (mutant-selective) solid tumors
GABRA5 NAM (RG1662) Down syndrome
lifastuzumab (RG7599)
NaPi2b ADC Pt resistant OC
PDL-1 MAb (RG7446) bladder cancer
CSF-1R MAb (RG7155)
PVNS and solid tumors
venetoclax (Bcl-2i, RG7601) + Gazyva DLBCL
Ang2-VEGF MAb (RG7221)
colorectal cancer
Status as of January 28, 2015
ocrelizumab (RG1594) PPMS
FIXa /FX bispecific MAb (RG6013) hemophilia A
cobimetinib TNBC
venetoclax (Bcl-2i, RG7601) + Gazyva CLL 1st line
venetoclax (Bcl-2i, RG7601) + Rituxan rel/ref FL
venetoclax (Bcl-2i, RG7601) CLL rel/ref
pictilisib PI3K inh (RG7321) solid tumors
SERD (RG6046)
ER+(HER2-neg) mBC
Avastin NSCLC adj
2014 2015 2017 and beyond
Indicates submission to health authorities has occurred.
* approved in EU; ** approved in US
Unless stated otherwise, submissions are planned to occur in US and EU.
Submissions of additional indications for existing
products
Projects currently in phase 2 and 3
36
Actemra systemic sclerosis
Perjeta HER2-pos. BC adj
Perjeta
HER2-pos. gastric cancer 1L
Zelboraf
melanoma adj.
Kadcyla +/- Perjeta
HER2-pos mBC 1st line
Kadcyla
HER2-pos gastric cancer 2L
Kadcyla
HER2-pos. BC adj
**Avastin (EU)
cervical cancer recurrent
Actemra giant cell arteritis
2016
*Avastin (US) rel. ovarian ca. Pt-resist
Avastin (US)
GBM
Gazyva DLBCL 1st line
Gazyva iNHL rituximab refractory
Gazyva follicular lymphoma 1st line
Neuroscience
Ophthalmology
Other
NME
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Perjeta
HER2-pos. mBC 2ndline
Lucentis (US) diabetic retinopathy
**Perjeta (EU) HER2-pos. BC neoadj
MabThera SC (EU) CLL
Status as of January 28, 2015
Avastin +Tarceva(EU)
EGFR mut+ NSCLC
*Avastin (US) ovarian cancer 1st line
*Avastin (US) rel. ovarian ca. Pt-sens
Kadcyla+Perjeta
HER2-pos. BC adj
Kadcyla+Perjeta
HER2-pos. BC neoadj
Kadcyla
HER2-pos. NSCLC
Major granted and pending approvals 2014
37
Neuroscience
Ophthalmology
Other
NME
Oncology
Immunology
Infectious Diseases
CardioMetabolism
EU
US
Approved Pending approvals
MabThera NHL sc formulation
March 2014
RoActemra
RA sc formulation April 2014
Xolair
chronic idiopathic urticaria
March 2014
Avastin
rel. ovarian ca. Pt-resist
August 2014
RoActemra
early RA
September 2014
Gazyvaro
CLL
July 2014
Avastin cervical cancer
Filed April 2014
Avastin cervical cancer
August 2014
alectinib ALECENSA ALK-pos rec/adv NSCLC
July 2014
Zelboraf
m. melanoma December 2014
Japan-Chugai
Perjeta BC neoadjuvant
Filed September 2014
cobimetinib + Zelboraf
m. melanoma
Filed September 2014
Lucentis diabetic retinopathy
Filed August 2014
Esbriet*
idiopathic pulmonary fibrosis
October 2014
Esbriet*
idiopathic pulmonary fibrosis
March 2011
* Newly acquired asset (Intermune) Status as of January 28, 2015
Avastin
rel. ovarian ca. Pt-resist
November 2014
MabThera SC CLL
Filed November 2014
cobimetinib + Zelboraf
m. melanoma
Filed December 2014